Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed Refractory Multiple Myeloma (RRMM). Including an Initial Report on Progression Free Survival in Blood, vol. 126, issue 23.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

OriginalsprogEngelsk
Publikationsdato3. dec. 2015
StatusUdgivet - 3. dec. 2015
Begivenhed57th American Society of Hematology Annual Meeting and Exposition - Orlando, USA
Varighed: 4. dec. 20158. dec. 2015

Konference

Konference57th American Society of Hematology Annual Meeting and Exposition
LandUSA
ByOrlando
Periode04/12/201508/12/2015

Citationsformater